TCI Wealth Advisors Inc. Sells 29 Shares of Stryker Corporation $SYK

TCI Wealth Advisors Inc. cut its holdings in shares of Stryker Corporation (NYSE:SYK) by 3.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 899 shares of the medical technology company’s stock after selling 29 shares during the period. TCI Wealth Advisors Inc.’s holdings in Stryker were worth $356,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the business. Goodman Advisory Group LLC bought a new stake in shares of Stryker in the first quarter worth approximately $32,000. City Holding Co. boosted its holdings in Stryker by 528.6% in the first quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock worth $33,000 after purchasing an additional 74 shares during the last quarter. Ridgewood Investments LLC grew its position in Stryker by 48.4% in the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after purchasing an additional 30 shares during the period. Ransom Advisory Ltd bought a new stake in Stryker in the 1st quarter worth approximately $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new stake in Stryker during the 1st quarter valued at $40,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

NYSE SYK opened at $368.64 on Friday. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The stock has a market cap of $140.93 billion, a price-to-earnings ratio of 48.83, a PEG ratio of 2.68 and a beta of 0.93. The company’s 50 day moving average is $386.11 and its two-hundred day moving average is $378.95.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. During the same period in the prior year, the company posted $2.81 earnings per share. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s payout ratio is presently 44.50%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This represents a 5.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on SYK shares. BTIG Research reaffirmed a “buy” rating on shares of Stryker in a report on Monday, July 14th. Wells Fargo & Company boosted their price target on Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research note on Friday, July 18th. Needham & Company LLC boosted their target price on shares of Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Finally, Evercore ISI upped their target price on shares of Stryker from $390.00 to $415.00 and gave the company an “outperform” rating in a report on Tuesday, July 8th. Fourteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $430.33.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.